NASDAQ:LMNX - Luminex Stock Price, Forecast & News

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex declared a quarterly dividend on Monday, December 9th. Shareholders of record on Thursday, December 19th will be paid a dividend of $0.09 per share on Wednesday, January 15th. This represents a $0.36 dividend on an annualized basis and a yield of 1.59%. The ex-dividend date is Wednesday, December 18th. View Luminex's Dividend History.

Luminex Co. (NASDAQ:LMNX) announced its quarterly earnings data on Monday, November, 4th. The medical instruments supplier reported ($0.12) EPS for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.05. The medical instruments supplier had revenue of $78.67 million for the quarter, compared to analyst estimates of $81.75 million. Luminex had a negative net margin of 2.93% and a negative return on equity of 2.38%. Luminex's revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.04 earnings per share. View Luminex's Earnings History.

Luminex is scheduled to release their next quarterly earnings announcement on Monday, February 10th 2020. View Earnings Estimates for Luminex.

Luminex will be holding an earnings conference call on Monday, February 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

3 analysts have issued 12-month price targets for Luminex's shares. Their forecasts range from $21.00 to $32.00. On average, they anticipate Luminex's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price. View Analyst Price Targets for Luminex.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

News articles about LMNX stock have been trending somewhat positive on Thursday, according to InfoTrie. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Luminex earned a news impact score of 1.6 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Luminex.

Luminex saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,070,000 shares, an increase of 8.7% from the December 15th total of 984,200 shares. Based on an average daily volume of 227,500 shares, the short-interest ratio is currently 4.7 days. Currently, 2.6% of the company's shares are sold short. View Luminex's Current Options Chain.

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), Micron Technology (MU), AbbVie (ABBV), Pfizer (PFE), Verizon Communications (VZ), Alphabet (GOOG), Starbucks (SBUX), AT&T (T), Exxon Mobil (XOM) and Nektar Therapeutics (NKTR).

Luminex's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Tocqueville Asset Management L.P. (0.14%), State of Alaska Department of Revenue (0.07%), Gibson Capital LLC (0.05%), Louisiana State Employees Retirement System (0.03%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Nachum Shamir and Todd C Bennett. View Institutional Ownership Trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Louisiana State Employees Retirement System and State of Alaska Department of Revenue. View Insider Buying and Selling for Luminex.

LMNX stock was purchased by a variety of institutional investors in the last quarter, including Gibson Capital LLC and Tocqueville Asset Management L.P.. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II and Nachum Shamir. View Insider Buying and Selling for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $22.59.

Luminex has a market capitalization of $1.02 billion and generates $315.82 million in revenue each year. The medical instruments supplier earns $18.51 million in net income (profit) each year or $0.48 on an earnings per share basis. Luminex employs 988 workers across the globe.View Additional Information About Luminex.

The official website for Luminex is http://www.luminexcorp.com/.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]